Compare First Citizens BancShares Inc (FCNCA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Novo Nordisk A/S — how do they compare? First Citizens BancShares Inc trades at $2,068.39 (market cap $22.94B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 7.2× First Citizens BancShares Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold First Citizens BancShares Inc for 29 Days and Novo Nordisk A/S for 116 Days on average.
| FCNCA | NVO | |
|---|---|---|
Market Cap | $22.94B | $165.31B |
Volume | 91,668 | 11,432,838 |
Sector | Sector/Thematic | Health |
52-Week High | $2.29K | $63.98 |
52-Week Low | $1.64K | $35.29 |
Typical Hold Time | 29 Days | 116 Days |
Dividend Yield | 0.41% | 4.71% |
Enterprise Value | — | $179.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,068.39, down slightly by 0.15% with a bearish technical signal. The company demonstrates strong fundamentals with a P/E of 11.08 and net income margin of 25.23%, having beaten earnings estimates for three consecutive quarters. Recent business developments include branch acquisitions and new financing initiatives, while analyst consensus shows 82% hold ratings with a $2,290 price target.
FCNCA presents a mixed outlook with strong profitability metrics offset by bearish technical indicators. Investment opportunity lies in continued earnings outperformance and strategic expansion, while risks include negative cash flow trends and institutional selling pressure. The stock offers value characteristics but requires monitoring of technical support levels near $2,028.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
